MitoImmune Therapeutics Inc.
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our mission is to increase healthy lifespan by developing treatments for mitochondrial dysfunction-related necrotic and inflammatory diseases.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Pharmaceuticals
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2018
Overview
Founded in August 2018, the company’s lead program is based on the breakthrough scientific findings of its founder Soon Ha Kim at LG Life Sciences which was acquired by LG Chem in the end of 2017. The LG team and the collaborators from various academic and medical organizations have identified the molecular mechanism and established proof of concept data for development of new therapies. MitoImmune Therapeutics exclusively in-licensed the technology from LG Chem. Last April in 2019, the company successfully secured $10.5M through Series A funding where KB Investment, BNH Investment, KDB Industrial Bank of Korea and SL Investment participated.
MitoImmune plans to initiate domestic and global Phase 2 clinical trials for diseases of high unmet medical needs such as IPF and GvHD and to carry out full-scale activities for global licensing deals. MitoImmune is committed to adding therapeutic indications that are important for millions of patients worldwide as well as rare genetic disorders to its development pipeline to make sure the pharmaceutical potential of MIT technology is realized to the fullest extent.
Vision & Strategy
MitoImmune Therapeutics Inc. pursues developing first- and best-in class drugs for incurable or rare diseases with high unmet medical needs by exploring regulated necrotic cell death and mitochondrial dysfunction, which are considered to be related to or initiated from broken homeostasis in iron, ROS, calcium, or immune. We will be dedicated that our innovative drugs are successfully delivered to patients through the long but valued journey along with experienced peer companies.
History
- Sustained and innovative R&D for the healthier life of mankind
2022
- Phase I IND clinical trial approved for SC formulation development
- PCT Application (BIM Tech. 2, Polymorphism 2, Stem cell 1)
- Use Patent Application (Covid-19 1, infertility 2)
2021
- Filed for a new utility patent on central nervous system disorders
- Filed for 2 BBB penetration platform BIM Technology patents
- Applied for 2 new polycrystalline patents
- Phase II clinical trial for head and neck cancer-CRIOM approved by the Ministry of Food and Drug Safety (multinational clinical trial)
- Phase II clinical trial for hematopoietic stem cell-CRIOM approved by the Ministry of Food and Drug Safety
- Raised KRW 27.5 billion in Series B investment (11 institutional investors)
- Phase II clinical trial for head and neck cancer-CRIOM approved by the U.S. FDA (multinational clinical trial)
2020
- Completed cGMP manufacturing of the clinically developed substance (MIT-001)
- Introduced a patent for a compound that prevents or treats mucositis (Catholic University Industry-University Cooperation Foundation)
- Registered as R&D service business
2019
- Company-affiliated research laboratory certified
- Certified as a venture company
- Established the R&D center (Munjeong-dong)
- Raised KRW 120 billion in Series 1 investment (4 institutional investors)
- Adopted an exclusive license for 4 drug patents and 6 utility patents (LG Chem)
2018
- MitoImmune Therapeutics' foundation and establishment
CEO Greetings
MitoImmune is an innovative biotech company with our proprietary technology that controls mitochondrial dysfunction and ferroptotic cell death, the key pathomechanism of intractable inflammatory diseases.
Currently, we are conducting global phase 2 clinical trials targeting disease with high unmet medical needs, and expanding into neurodegenerative diseases and intractable inflammatiry diseases through our core technologies. In addition, our future roadmap includes expansion into the immuno-oncology area through the accumulative knowledge related to ferroptosis.
In order to secure the continuity of innovative research activities and growth engines, we are internalizing our expertise by attracting key talents and establishing an expert network.
All members of MitoImmune will be dedicated to providing better treatment options to patients and restoring their rights to a higher quality of life. We look forward to your continuous interest and support.